Danaher Corporation has entered into a definitive agreement with General Electric (GE) Company to acquire a very lucrative Biopharma business unit of GE Life Sciences. Biopharma unit of GE Life Sciences, is the leading provider of instruments, consumables, and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. The business comprises process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and service.
Rajiv Kalia - Associate Vice President : Healthcare Research, at MarketsandMarkets™, shares his Point of View as mentioned below:
This GE deal is one of the largest in the bioprocess industry and Danaher’s biggest takeover by a wide margin as it gains access to GE's coveted bioprocessing assets. This acquisition will help Danaher to have a strongest customer base in this section of the market. It will allow Danaher to serve to a broad range of end users as compared to its competitors like Merck KGaA and Thermo Fisher Scientific.
Both the GE and Danaher are the prominent players in the process chromatography space. Acquiring GE’s strong product portfolio of chromatography hardware and consumables will help Danaher to significantly increase its presence in this market, and help Danaher to emerge as a leader in the process chromatography hardware and consumables market.
Similarly, in the single use bioreactor market, addition of GE’s products such as Xcellerex and WAVE bioreactors under Danaher’s umbrella, complements its current biologics workflow solutions and make it one of the leading provider of bioprocessing solutions in the market. While, adding GE’s filtration products to Danaher’s portfolio further boosted its leading position in this market.
We view the acquisition as highly strategic, as Danaher gains access to GE's coveted bioprocessing assets and help in long term growth and build end-to-end bioprocessing solutions for its customers. We believe post the acquisition Danaher will solidify its position as one of the leaders in the chromatography and bioprocessing space.
GE HEALTHCARE LED THE PREPARATIVE AND PROCESS CHROMATOGRAPHY MARKET IN 2017
Source: MarketsandMarkets™ Analysis
Earlier, Danaher Corporation had announced on 25th of February, that it has entered into a definitive agreement with General Electric (GE) Company to acquire the Biopharma business of GE Life Sciences for approximately USD 21.4 billion. The business will be established as a stand-alone operating company within Danaher's Life Sciences segment. Acquisition of this segment is expected to be completed in the fourth quarter of calendar year 2019, upon regulatory approvals.